{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["12"],"submitter":["Brue T"],"pubmed_abstract":["<h4>Objective</h4>Efficacy of pharmacological treatments for acromegaly has been assessed in many clinical or real-world studies but no study was interested in economics evaluation of these treatments in France. Therefore, the objective of this study was to estimate the cost-utility of second-line pharmacological treatments in acromegaly patients.<h4>Methods</h4>A Markov model was developed to follow a cohort of 1,000 patients for a lifetime horizon. First-generation somatostatin analogues (FGSA), pegvisomant, pasireotide and pegvisomant combined with FGSA (off label) were compared. Efficacy was defined as the normalization of insulin-like growth factor-1 (IGF-1) concentration and was obtained from pivotal trials and adjusted by a network meta-analysis. Costs data were obtained from French"],"journal":["Frontiers in endocrinology"],"pagination":["745843"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8531881"],"repository":["biostudies-literature"],"pubmed_title":["Cost-Utility of Acromegaly Pharmacological Treatments in a French Context."],"pmcid":["PMC8531881"],"pubmed_authors":["Drui D","Raverot G","Rodien P","Henocque R","Juban L","Brue T","Salvi L","Marie L","Delemer B","Chanson P"],"additional_accession":[]},"is_claimable":false,"name":"Cost-Utility of Acromegaly Pharmacological Treatments in a French Context.","description":"<h4>Objective</h4>Efficacy of pharmacological treatments for acromegaly has been assessed in many clinical or real-world studies but no study was interested in economics evaluation of these treatments in France. Therefore, the objective of this study was to estimate the cost-utility of second-line pharmacological treatments in acromegaly patients.<h4>Methods</h4>A Markov model was developed to follow a cohort of 1,000 patients for a lifetime horizon. First-generation somatostatin analogues (FGSA), pegvisomant, pasireotide and pegvisomant combined with FGSA (off label) were compared. Efficacy was defined as the normalization of insulin-like growth factor-1 (IGF-1) concentration and was obtained from pivotal trials and adjusted by a network meta-analysis. Costs data were obtained from French","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021","modification":"2026-07-16T14:42:05.451Z","creation":"2025-04-05T22:19:52.07Z"},"accession":"S-EPMC8531881","cross_references":{"pubmed":["34690933"],"doi":["10.3389/fendo.2021.745843"]}}